Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia

  1. Pizzorno, Andrés
  2. Padey, Blandine
  3. Julien, Thomas
  4. Trouillet-Assant, Sophie
  5. Traversier, Aurélien
  6. Errazuriz-Cerda, Elisabeth
  7. Fouret, Julien
  8. Dubois, Julia
  9. Gaymard, Alexandre
  10. Lescure, François-Xavier
  11. Dulière, Victoria
  12. Brun, Pauline
  13. Constant, Samuel
  14. Poissy, Julien
  15. Lina, Bruno
  16. Yazdanpanah, Yazdan
  17. Terrier, Olivier
  18. Rosa-Calatrava, Manuel

Download
1-s2.0-S2666379120300756-main.pdf 3,74MB
WeightNameValue
1000 Titel
  • Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia
1000 Autor/in
  1. Pizzorno, Andrés |
  2. Padey, Blandine |
  3. Julien, Thomas |
  4. Trouillet-Assant, Sophie |
  5. Traversier, Aurélien |
  6. Errazuriz-Cerda, Elisabeth |
  7. Fouret, Julien |
  8. Dubois, Julia |
  9. Gaymard, Alexandre |
  10. Lescure, François-Xavier |
  11. Dulière, Victoria |
  12. Brun, Pauline |
  13. Constant, Samuel |
  14. Poissy, Julien |
  15. Lina, Bruno |
  16. Yazdanpanah, Yazdan |
  17. Terrier, Olivier |
  18. Rosa-Calatrava, Manuel |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-07-21
1000 Erschienen in
1000 Quellenangabe
  • 1(4):100059
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.xcrm.2020.100059 |
1000 Ergänzendes Material
  • https://www.sciencedirect.com/science/article/pii/S2666379120300756#appsec2 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge. However, the scarcity of biologically relevant pre-clinical models of SARS-CoV-2 infection imposes a significant barrier for scientific and medical progress, including the rapid transition of potentially effective treatments to the clinical setting. We use reconstituted human airway epithelia to isolate and then characterize the viral infection kinetics, tissue-level remodeling of the cellular ultrastructure, and transcriptional early immune signatures induced by SARS-CoV-2 in a physiologically relevant model. Our results emphasize distinctive transcriptional immune signatures between nasal and bronchial HAE, both in terms of kinetics and intensity, hence suggesting putative intrinsic differences in the early response to SARS-CoV-2 infection. Most important, we provide evidence in human-derived tissues on the antiviral efficacy of remdesivir monotherapy and explore the potential of the remdesivir-diltiazem combination as an option worthy of further investigation to respond to the still-unmet COVID-19 medical need.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal repurposing
lokal diltiazem
lokal innate immune response
lokal coronavirus
lokal remdesivir
lokal cell ultrastructure remodeling
lokal drug combination
lokal SARS-CoV-2
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UGl6em9ybm8sIEFuZHLDqXM=|https://frl.publisso.de/adhoc/uri/UGFkZXksIEJsYW5kaW5l|https://frl.publisso.de/adhoc/uri/SnVsaWVuLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/VHJvdWlsbGV0LUFzc2FudCwgU29waGll|https://frl.publisso.de/adhoc/uri/VHJhdmVyc2llciwgQXVyw6lsaWVu|https://frl.publisso.de/adhoc/uri/RXJyYXp1cml6LUNlcmRhLCBFbGlzYWJldGg=|https://frl.publisso.de/adhoc/uri/Rm91cmV0LCBKdWxpZW4=|https://frl.publisso.de/adhoc/uri/RHVib2lzLCBKdWxpYQ==|https://frl.publisso.de/adhoc/uri/R2F5bWFyZCwgQWxleGFuZHJl|https://frl.publisso.de/adhoc/uri/TGVzY3VyZSwgRnJhbsOnb2lzLVhhdmllcg==|https://frl.publisso.de/adhoc/uri/RHVsacOocmUsIFZpY3Rvcmlh|https://frl.publisso.de/adhoc/uri/QnJ1biwgUGF1bGluZQ==|https://frl.publisso.de/adhoc/uri/Q29uc3RhbnQsIFNhbXVlbA==|https://frl.publisso.de/adhoc/uri/UG9pc3N5LCBKdWxpZW4=|https://frl.publisso.de/adhoc/uri/TGluYSwgQnJ1bm8=|https://frl.publisso.de/adhoc/uri/WWF6ZGFucGFuYWgsIFlhemRhbg==|https://frl.publisso.de/adhoc/uri/VGVycmllciwgT2xpdmllcg==|https://frl.publisso.de/adhoc/uri/Um9zYS1DYWxhdHJhdmEsIE1hbnVlbA==
1000 Label
1000 Förderer
  1. Institut National de la Santé et de la Recherche Médicale |
  2. Centre National de la Recherche Scientifique |
  3. Fondation Mérieux |
1000 Fördernummer
  1. -
  2. -
  3. -
1000 Förderprogramm
  1. REACTing (REsearch & ACtion emergING infectious diseases)
  2. -
  3. Mérieux research grants
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Institut National de la Santé et de la Recherche Médicale |
    1000 Förderprogramm REACTing (REsearch & ACtion emergING infectious diseases)
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Centre National de la Recherche Scientifique |
    1000 Förderprogramm -
    1000 Fördernummer -
  3. 1000 joinedFunding-child
    1000 Förderer Fondation Mérieux |
    1000 Förderprogramm Mérieux research grants
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6422098.rdf
1000 Erstellt am 2020-07-23T11:08:06.570+0200
1000 Erstellt von 21
1000 beschreibt frl:6422098
1000 Bearbeitet von 21
1000 Zuletzt bearbeitet Thu Jul 23 11:09:20 CEST 2020
1000 Objekt bearb. Thu Jul 23 11:09:05 CEST 2020
1000 Vgl. frl:6422098
1000 Oai Id
  1. oai:frl.publisso.de:frl:6422098 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source